ArticleThe journal of pathology. Clinical research2026
Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coordinated Expression of ADC TargetsCurrent issues in molecular biology · 2026Article
- The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Recent advancements in antibody-drug conjugates, including FDA-approved therapies targeting Nectin-4 and Trop-2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug-associated adverse effects raise the question of whether patients should be selected based on a biomarker study to achieve optimal outcomes. A better understanding of the patterns and clinicopathological significance of Nectin-4 and Trop-2 expression in UTUC remains to be achieved. We generated tissue microarrays (TMAs) with 120 UTUC specimens from patients who underwent nephroureterectomy at our institution and evaluated the expression of Nectin-4 and Trop-2 in tumor and non-tumor tissue. Nectin-4 expression was significantly higher in both invasive and noninvasive high-grade UTUC compared to noninvasive low-grade tumors. In contrast, Trop-2 expression did not vary significantly between noninvasive low-grade and high-grade tumors. When analyzed by stage, Nectin-4 expression was significantly elevated in tumors of higher stages than in early-stage tumors, similar to Trop-2 expression. Although both Nectin-4 and Trop-2 were broadly expressed in tumor and adjacent non-tumor urothelium, a subset of patients demonstrated low expression in non-tumor tissue but high expression in tumor tissue. Nectin-4 expression, but not Trop-2, was significantly correlated with the Ki-67 index, indicating that they may have different roles in tumor proliferation. The differential expression of Nectin-4 and Trop-2 by tumor grade and stage highlights their potential relevance in guiding targeted therapy for UTUC. Notably, a subset of patients exhibits high expression in tumor tissue, accompanied by low expression in adjacent non-tumor urothelium, suggesting a favorable therapeutic index for antibody-drug conjugate therapy. These findings support the need for further biomarker-driven studies to optimize patient selection and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.